Themis Medicare Share Price
Sector: Major Drugs
131.30 -2.00 (-1.50%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
129.50
Today’s High
139.00
52 Week Low
115.05
52 Week High
313.65
131.05 -2.49 (-1.86%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
129.49
Today’s High
133.54
52 Week Low
115.00
52 Week High
317.00
Key Metrics
- Market Cap (In Cr) 1215.78
- Beta 0.96
- Div. Yield (%) 0.37
- P/B 3.25
- TTM P/E 52.59
- Peg Ratio 3.97
- Sector P/E 26.62
- Open Price 139
- Prev Close 133.3
Themis Medicare Analysis
Price Analysis
-
1 Week-0.61%
-
3 Months-47.06%
-
6 Month-49.73%
-
YTD-49.33%
-
1 Year-36.45%
Risk Meter
- 59% Low risk
- 59% Moderate risk
- 59% Balanced Risk
- 59% High risk
- 59% Extreme risk
Themis Medicare News
Stocks to Watch: Zee, Waaree Energies, Bharti Airtel, NTPC, GVK Power and more
1 min read . 19 Nov 2024Themis Medicare Financials
- INCOME
- BALANCE SHEET
- Cashflow
- Period
- 2024
- Total Revenue
- 381.76
- Selling/ General/ Admin Expenses Total
- 157.04
- Depreciation/ Amortization
- 12.25
- Other Operating Expenses Total
- 18.3
- Total Operating Expense
- 342.5
- Operating Income
- 39.26
- Net Income Before Taxes
- 53.44
- Net Income
- 43.52
- Diluted Normalized EPS
- 4.72
- Period
- 2024
- Total Assets
- 566.42
- Total Liabilities
- 188.75
- Total Equity
- 377.67
- Tangible Book Valueper Share Common Eq
- 40.97
- Period
- 2024
- Cashfrom Operating Activities
- 22.09
- Cashfrom Investing Activities
- -15.95
- Cashfrom Financing Activities
- -8.77
- Net Changein Cash
- -2.62
- Period
- 2023
- Total Revenue
- 354.32
- Selling/ General/ Admin Expenses Total
- 131.54
- Depreciation/ Amortization
- 10.49
- Other Operating Expenses Total
- 20.4
- Total Operating Expense
- 297.37
- Operating Income
- 56.96
- Net Income Before Taxes
- 72.51
- Net Income
- 56.9
- Diluted Normalized EPS
- 6.17
- Period
- 2023
- Total Assets
- 513.96
- Total Liabilities
- 174.51
- Total Equity
- 339.44
- Tangible Book Valueper Share Common Eq
- 36.8
- Period
- 2023
- Cashfrom Operating Activities
- 16.09
- Cashfrom Investing Activities
- -23.96
- Cashfrom Financing Activities
- 0.14
- Net Changein Cash
- -7.73
- Period
- 2022
- Total Revenue
- 394.61
- Selling/ General/ Admin Expenses Total
- 111.63
- Depreciation/ Amortization
- 9.48
- Other Operating Expenses Total
- 18.86
- Total Operating Expense
- 308.46
- Operating Income
- 86.16
- Net Income Before Taxes
- 95.26
- Net Income
- 72.88
- Diluted Normalized EPS
- 7.91
- Period
- 2022
- Total Assets
- 427.78
- Total Liabilities
- 140.29
- Total Equity
- 287.49
- Tangible Book Valueper Share Common Eq
- 31.14
- Period
- 2022
- Cashfrom Operating Activities
- 34.39
- Cashfrom Investing Activities
- -15.59
- Cashfrom Financing Activities
- -17.55
- Net Changein Cash
- 1.26
- Period
- 2021
- Total Revenue
- 230.67
- Selling/ General/ Admin Expenses Total
- 79.82
- Depreciation/ Amortization
- 8.55
- Other Operating Expenses Total
- 14.16
- Total Operating Expense
- 189.72
- Operating Income
- 40.95
- Net Income Before Taxes
- 41.33
- Net Income
- 35.7
- Diluted Normalized EPS
- 3.88
- Period
- 2021
- Total Assets
- 371.14
- Total Liabilities
- 152.63
- Total Equity
- 218.51
- Tangible Book Valueper Share Common Eq
- 23.65
- Period
- 2021
- Cashfrom Operating Activities
- 56.98
- Cashfrom Investing Activities
- -15.65
- Cashfrom Financing Activities
- -25.65
- Net Changein Cash
- 15.68
- Period
- 2020
- Total Revenue
- 201.59
- Selling/ General/ Admin Expenses Total
- 83.46
- Depreciation/ Amortization
- 8.27
- Other Operating Expenses Total
- 7.79
- Total Operating Expense
- 174.13
- Operating Income
- 27.46
- Net Income Before Taxes
- 26.87
- Net Income
- 24.78
- Diluted Normalized EPS
- 2.7
- Period
- 2020
- Total Assets
- 349.91
- Total Liabilities
- 166.89
- Total Equity
- 183.02
- Tangible Book Valueper Share Common Eq
- 19.76
- Period
- 2020
- Cashfrom Operating Activities
- 0.33
- Cashfrom Investing Activities
- -5.47
- Cashfrom Financing Activities
- 6.72
- Net Changein Cash
- 1.59
- Period
- 2019
- Total Revenue
- 183.75
- Selling/ General/ Admin Expenses Total
- 89.4
- Depreciation/ Amortization
- 7.99
- Other Operating Expenses Total
- 8.64
- Total Operating Expense
- 184.96
- Operating Income
- -1.2
- Net Income Before Taxes
- -12.6
- Net Income
- -10.74
- Diluted Normalized EPS
- -1.17
- Period
- 2019
- Total Assets
- 314.11
- Total Liabilities
- 156.02
- Total Equity
- 158.09
- Tangible Book Valueper Share Common Eq
- 17.04
- Period
- 2019
- Cashfrom Operating Activities
- 10.92
- Cashfrom Investing Activities
- -3.72
- Cashfrom Financing Activities
- -9.94
- Net Changein Cash
- -2.74
- Period
- 2018
- Total Revenue
- 211.71
- Selling/ General/ Admin Expenses Total
- 90.88
- Depreciation/ Amortization
- 7.42
- Other Operating Expenses Total
- 9.35
- Total Operating Expense
- 193.94
- Operating Income
- 17.77
- Net Income Before Taxes
- 11.34
- Net Income
- 11.3
- Diluted Normalized EPS
- 1.23
- Period
- 2018
- Total Assets
- 305.28
- Total Liabilities
- 136.38
- Total Equity
- 168.91
- Tangible Book Valueper Share Common Eq
- 18.19
- Period
- 2018
- Cashfrom Operating Activities
- 7.85
- Cashfrom Investing Activities
- -0.04
- Cashfrom Financing Activities
- -9.11
- Net Changein Cash
- -1.3
- Period
- 2024-12-31
- Total Revenue
- 93.81
- Selling/ General/ Admin Expenses Total
- 24.95
- Depreciation/ Amortization
- 2.54
- Other Operating Expenses Total
- 31.83
- Total Operating Expense
- 87.82
- Operating Income
- 5.99
- Net Income Before Taxes
- 1.66
- Net Income
- 0.52
- Diluted Normalized EPS
- 0.06
- Period
- 2024-12-31
- Period
- 2024-12-31
- Period
- 2024-09-30
- Total Revenue
- 117.01
- Selling/ General/ Admin Expenses Total
- 24.38
- Depreciation/ Amortization
- 2.45
- Other Operating Expenses Total
- 33.87
- Total Operating Expense
- 102.33
- Operating Income
- 14.68
- Net Income Before Taxes
- 17.8
- Net Income
- 14.29
- Diluted Normalized EPS
- 1.55
- Period
- 2024-09-30
- Total Assets
- 602.21
- Total Liabilities
- 190.2
- Total Equity
- 412.02
- Tangible Book Valueper Share Common Eq
- 44.72
- Period
- 2024-09-30
- Cashfrom Operating Activities
- 32.97
- Cashfrom Investing Activities
- -9.98
- Cashfrom Financing Activities
- -23.21
- Net Changein Cash
- -0.22
- Period
- 2024-06-30
- Total Revenue
- 122.99
- Selling/ General/ Admin Expenses Total
- 21.6
- Depreciation/ Amortization
- 2.41
- Other Operating Expenses Total
- 30.95
- Total Operating Expense
- 96.22
- Operating Income
- 26.77
- Net Income Before Taxes
- 31.35
- Net Income
- 24.68
- Diluted Normalized EPS
- 2.68
- Period
- 2024-06-30
- Period
- 2024-06-30
- Period
- 2024-03-31
- Total Revenue
- 97.82
- Selling/ General/ Admin Expenses Total
- 22.46
- Depreciation/ Amortization
- 3.06
- Other Operating Expenses Total
- 26.83
- Total Operating Expense
- 91.58
- Operating Income
- 6.24
- Net Income Before Taxes
- 8.75
- Net Income
- 6.64
- Diluted Normalized EPS
- 0.72
- Period
- 2024-03-31
- Total Assets
- 566.42
- Total Liabilities
- 188.75
- Total Equity
- 377.67
- Tangible Book Valueper Share Common Eq
- 40.97
- Period
- 2024-03-31
- Cashfrom Operating Activities
- 22.09
- Cashfrom Investing Activities
- -15.95
- Cashfrom Financing Activities
- -8.77
- Net Changein Cash
- -2.62
- Period
- 2023-12-31
- Total Revenue
- 82.51
- Selling/ General/ Admin Expenses Total
- 19.92
- Depreciation/ Amortization
- 3.1
- Other Operating Expenses Total
- 28.05
- Total Operating Expense
- 77.55
- Operating Income
- 4.97
- Net Income Before Taxes
- 8.22
- Net Income
- 7.37
- Diluted Normalized EPS
- 0.8
- Period
- 2023-12-31
- Period
- 2023-12-31
- Period
- 2023-09-30
- Total Revenue
- 104.78
- Selling/ General/ Admin Expenses Total
- 19.86
- Depreciation/ Amortization
- 3.07
- Other Operating Expenses Total
- 30.58
- Total Operating Expense
- 95.45
- Operating Income
- 9.34
- Net Income Before Taxes
- 13.96
- Net Income
- 11.32
- Diluted Normalized EPS
- 1.23
- Period
- 2023-09-30
- Total Assets
- 548.47
- Total Liabilities
- 184.33
- Total Equity
- 364.14
- Tangible Book Valueper Share Common Eq
- 39.5
- Period
- 2023-09-30
- Cashfrom Operating Activities
- 16.7
- Cashfrom Investing Activities
- -9.84
- Cashfrom Financing Activities
- -5.93
- Net Changein Cash
- 0.93
- Period
- 2023-06-30
- Total Revenue
- 96.65
- Selling/ General/ Admin Expenses Total
- 20.17
- Depreciation/ Amortization
- 3.03
- Other Operating Expenses Total
- 25.67
- Total Operating Expense
- 77.93
- Operating Income
- 18.72
- Net Income Before Taxes
- 22.52
- Net Income
- 18.19
- Diluted Normalized EPS
- 1.97
- Period
- 2023-06-30
- Period
- 2023-06-30
- Period
- 2023-03-31
- Total Revenue
- 80.1
- Selling/ General/ Admin Expenses Total
- 17.72
- Depreciation/ Amortization
- 2.8
- Other Operating Expenses Total
- 24.1
- Total Operating Expense
- 72.42
- Operating Income
- 7.68
- Net Income Before Taxes
- 10.29
- Net Income
- 8.41
- Diluted Normalized EPS
- 0.91
- Period
- 2023-03-31
- Total Assets
- 513.96
- Total Liabilities
- 174.51
- Total Equity
- 339.44
- Tangible Book Valueper Share Common Eq
- 36.8
- Period
- 2023-03-31
- Cashfrom Operating Activities
- 16.09
- Cashfrom Investing Activities
- -23.96
- Cashfrom Financing Activities
- 0.14
- Net Changein Cash
- -7.73
- Period
- 2022-12-31
- Total Revenue
- 88.78
- Selling/ General/ Admin Expenses Total
- 16.62
- Depreciation/ Amortization
- 2.67
- Other Operating Expenses Total
- 23.46
- Total Operating Expense
- 76.19
- Operating Income
- 12.59
- Net Income Before Taxes
- 17.5
- Net Income
- 13.31
- Diluted Normalized EPS
- 1.44
- Period
- 2022-12-31
- Period
- 2022-12-31
Forecast
Income Sheet (In Cr)
Net Income Vs Revenue
Returns Metrics (In Cr)
ROA Vs ROE
Forecast
Balance Sheet
Asset vs Liability
Forecast
Cash Flow
Operating vs Investing
Themis Medicare Technical
Moving Average
SMA
- 5 Day136.74
- 10 Day131.82
- 20 Day138.14
- 50 Day157.82
- 100 Day210.64
- 300 Day234.52
Themis Medicare Peers
- Price
- Ratio
- Name
- Latest Price
- Change
- % Change
- 52W High
- 52W Low
- Mkt. Cap
- Unichem Laboratories
- 616.1
- -3.5
- -0.56
- 949.85
- 507.2
- 4379.4
- Jagsonpal Pharmaceuticals
- 233.2
- -10.35
- -4.25
- 328.02
- 109.42
- 1548.42
- Themis Medicare
- 131.3
- -2
- -1.5
- 313.65
- 115.05
- 1215.78
- Ind-swift Laboratories
- 75.94
- -4.6
- -5.71
- 186
- 74
- 450.67
- Brooks Laboratories
- 139
- -1
- -0.71
- 202.8
- 72.51
- 409.45
- Name
- P/E (X)
- P/B (X)
- ROE %
- OPM
- Unichem Laboratories
- -
- 1.84
- -2.1
- -3.99
- Jagsonpal Pharmaceuticals
- 71.13
- 8.5
- 13.79
- 9.21
- Themis Medicare
- 28.29
- 3.25
- 18.03
- 14.96
- Ind-swift Laboratories
- 3.42
- 0.51
- 13.45
- 8.52
- Brooks Laboratories
- -
- 5.6
- -21.61
- -27.47
Themis Medicare Shareholding
Shareholding Pattern
*Promoter pledging: 1.63%
Shareholding Trend
Shareholding(%) v/s Date
Corporate Actions
- Board Meeting
- AGM
- Dividends
- Bonus
- Split
- Rights
- Meeting Date
- Purpose
- 14-Feb-25
- Quarterly Results
- 25-Oct-24
- Quarterly Results
- 26-Jul-24
- Quarterly Results
- 14-May-24
- Audited Results & Final Dividend
- 10-Feb-24
- Quarterly Results
- 04-Nov-23
- Quarterly Results
- 12-Aug-23
- Quarterly Results
- 10-Aug-23
- Quarterly Results
- 13-May-23
- Audited Results, Dividend & Stock Split
- 03-Feb-23
- Quarterly Results
- Meeting Date
- Announced on
- Purpose
- 25-Mar-25
- 20-Feb-25
- POM
- 22-Jul-24
- 15-May-24
- AGM
- 09-Apr-24
- 11-Mar-24
- POM
- 17-Nov-23
- 16-Oct-23
- POM
- 09-Sept-23
- 22-Jul-23
- AGM
- 19-Sept-22
- 23-May-22
- AGM
- 20-Jun-22
- 17-May-22
- POM
- Announced on
- Record Date
- Ex-Dividend
- Dividend Value
- 14-May-24
- -
- 12-Jul-24
- 0.5
- 15-May-23
- -
- 01-Sept-23
- 5
- 23-May-22
- -
- 08-Sept-22
- 5
- 27-May-21
- -
- 08-Sept-21
- 4.3

- Ex-Splits
- Old FV
- New FV
- Description
- 10-Oct-23
- 10
- 1
- Stock split from Rs. 10/- to Re. 1/-.
